<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336839</url>
  </required_header>
  <id_info>
    <org_study_id>11536</org_study_id>
    <nct_id>NCT04336839</nct_id>
  </id_info>
  <brief_title>Portal Vein Resection in Pancreatic Neuroendocrine Tumours</brief_title>
  <acronym>PVNET</acronym>
  <official_title>Vascular Resection During Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms (PanNENs): a Comparative Single Centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Free Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Free Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The limited evidence on the value of portal vein resection in patients with borderline
      resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective
      multicentre study amongst centres with specific interest in the management of PanNENs and
      with experience on vascular reconstruction. Unlike previous studies on pancreatic cancer, it
      is more difficult to standardise the comparative parameters as the definition of borderline
      resectable disease has never been published for PanNENs. Similarly, different histological
      classifications make impossible to collect data exclusively on T3 tumours. Therefore, we aim
      to compare the short and long-term outcomes (including the impact of the histological depth
      of vascular invasion on survival) between patients undergoing standard PD and PD with portal
      vein resection for PanNENs, (regardless of T stage), by collecting and analysing
      retrospective data in this single centre study
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>total of 2 years retrospective follow up</time_frame>
    <description>Time from surgery to disease progression, or death or completion of follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity and mortality rate</measure>
    <time_frame>total of 2 years retrospective follow up</time_frame>
    <description>Postoperative morbidity and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology predictive value</measure>
    <time_frame>total of 2 years retrospective follow up</time_frame>
    <description>Predictive value of histologically proven invasion of the portal vein adventitia</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreas Neoplasm</condition>
  <condition>Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Portal vein resection / reconstruction</intervention_name>
    <description>Portal vein resection and reconstruction, with or without concommitant arterial resection</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients operated for pancreatic neuroendocrine tumours within a single tertiary referal
        centre
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients undergoing pancreaticoduodenectomy (Whipple's or Pylorus Preserving
        Pancreaticoduodenectomy) for sporadic PanNENs of the head of the pancreas of any stage (R0
        or R1 resections) operated from 1st January 2007 up to 31st December 2016 inclusive.

        Exclusion Criteria:

          -  Multiple Neuroendocrine Neoplasia (MEN) syndrome or other genetic background

          -  Age &lt;18 years old

          -  Total pancreatectomy or different operation rather than PD

          -  R2 Resections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe K Fusai, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free London NHS Foundation Trust &amp; University College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panagis M Lykoudis, MD, MSc</last_name>
    <phone>+44(0)7413738787</phone>
    <email>p.lykoudis@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe K Fusai, MD MS</last_name>
    <phone>0044(0)2077940500</phone>
    <phone_ext>33603</phone_ext>
    <email>g.fusai@ucl.ac.uk</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Sakamoto E, Hasegawa H, Ogiso S, Igami T, Mori T, Mizuno T, Hattori K, Sugimoto M, Fukami Y. Curative resection for a pancreatic endocrine carcinoma involving the portal vein. Hepatogastroenterology. 2004 Nov-Dec;51(60):1849-51.</citation>
    <PMID>15532841</PMID>
  </results_reference>
  <results_reference>
    <citation>Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005 May;241(5):776-83; discussion 783-5.</citation>
    <PMID>15849513</PMID>
  </results_reference>
  <results_reference>
    <citation>van Geenen RC, ten Kate FJ, de Wit LT, van Gulik TM, Obertop H, Gouma DJ. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery. 2001 Feb;129(2):158-63.</citation>
    <PMID>11174708</PMID>
  </results_reference>
  <results_reference>
    <citation>Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, Imber CJ, Fusai G; UK Vascular Resection in Pancreatic Cancer Study Group. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014 Mar;218(3):401-11. doi: 10.1016/j.jamcollsurg.2013.11.017. Epub 2013 Nov 27.</citation>
    <PMID>24484730</PMID>
  </results_reference>
  <results_reference>
    <citation>Elberm H, Ravikumar R, Sabin C, Abu Hilal M, Al-Hilli A, Aroori S, Bond-Smith G, Bramhall S, Coldham C, Hammond J, Hutchins R, Imber C, Preziosi G, Saleh A, Silva M, Simpson J, Spoletini G, Stell D, Terrace J, White S, Wigmore S, Fusai G. Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. Eur J Surg Oncol. 2015 Nov;41(11):1500-7. doi: 10.1016/j.ejso.2015.08.158. Epub 2015 Aug 28.</citation>
    <PMID>26346183</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>portal vein resection</keyword>
  <keyword>pancreatic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

